B. Metzler Seel. Sohn & Co. Ag Seagen Inc. Transaction History

B. Metzler Seel. Sohn & Co. Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$191.51 - $216.16 $229,237 - $258,743	-1,197 Reduced 22.9%	4,030 $854,000
Q2 2023 Aug 11, 2023	SELL	$187.64 - $206.25 $101,700 - $111,787	-542 Reduced 9.4%	5,227 $1.01 Million
Q1 2023 May 10, 2023	BUY	$127.59 - $203.08 $109,472 - $174,242	858 Added 17.47%	5,769 $1.17 Million
Q4 2022 Feb 13, 2023	SELL	$117.37 - $139.17 $63,145 - $74,873	-538 Reduced 9.87%	4,911 $631,000
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $56,137 - $74,745	415 Added 8.24%	5,449 $746,000
Q2 2022 Aug 12, 2022	SELL	$108.81 - $179.33 $55,819 - $91,996	-513 Reduced 9.25%	5,034 $891,000
Q1 2022 May 10, 2022	BUY	$119.61 - $157.85 $85,401 - $112,704	714 Added 14.77%	5,547 $799,000
Q4 2021 Feb 11, 2022	BUY	$142.57 - $190.86 $689,040 - $922,426	4,833 New	4,833 $760,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of B. Metzler Seel. Sohn & Co. Ag, based on Form 13F filings with the SEC.

Stay updated on B. Metzler Seel. Sohn & Co. Ag with notifications on news.